Lorsan CH Tablet is a fixed-dose combination medication containing Losartan, an angiotensin II receptor blocker (ARB), and Chlorthalidone, a thiazide-like diuretic. This formulation is primarily used to manage hypertension (high blood pressure), helping to reduce the risk of cardiovascular events such as heart attack and stroke, particularly in patients with associated risk factors like left ventricular hypertrophy or diabetes.
Losartan works by selectively blocking the binding of angiotensin II to the AT1 receptor, thereby relaxing blood vessels and lowering blood pressure. It also helps protect the kidneys from damage due to high blood pressure or diabetes. Chlorthalidone, on the other hand, enhances the elimination of sodium and water through urine by inhibiting sodium reabsorption in the distal tubules of the kidneys. This diuretic effect reduces plasma volume and decreases vascular resistance, contributing to blood pressure control.
This dual-action combination ensures effective and sustained antihypertensive therapy by addressing both vascular resistance and fluid retention. The inclusion of a low dose of Chlorthalidone minimizes the risk of electrolyte imbalance and dehydration while retaining efficacy.
Lorsan CH is typically administered once daily and may be used as monotherapy or in combination with other antihypertensive agents, especially in patients who do not achieve adequate blood pressure control with a single agent. It is well-suited for long-term management of hypertension in adults and offers the advantage of improved compliance due to the convenience of a single-tablet regimen.
This medication is part of the Hypertension/Blood Pressure and Cardiovascular therapeutic segments and may also be listed under General medicines due to its broad use in clinical practice.